TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 14, 2021 13:49 JST
Source:
Eisai
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.
As major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients. Poster presentations regarding lemborexant are also planned, including the results of a pilot study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment. Additionally, for perampanel, a global pooled analysis results from the real-world experiences including early adjunctive use or monotherapy will be presented at poster sessions.
Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with the disease and their families.
For more information, visit
https://www.eisai.com/news/2021/news202127.html
.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
More Press release >>
Latest Press Release
Mazda Begins Demonstration Experiment of Onboard CO2 Capture System
Nov 18, 2025 00:38 JST
Pushing Hydrogen Engine Technology to New Heights in the Super Taikyu Series Final Race
Nov 18, 2025 00:00 JST
Fujitsu launches business creation lab in collaboration with AWS Japan
Nov 17, 2025 23:41 JST
NTT DOCOMO Achieves Successful Outdoor Trial of AI-Driven Wireless Interface Toward 6G
Nov 17, 2025 23:05 JST
Destinator Earns the Highest Rating of Five Stars in 2025 ASEAN NCAP
Nov 17, 2025 22:32 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Nov 17, 2025 22:08 JST
NEC Advances Research Information Infrastructure for Open Science
Nov 17, 2025 21:38 JST
Mitsubishi Shipbuilding Delivers Large Car Ferry KEYAKI to Shin Nihonkai Ferry and Japan Railway Construction, Transport and Technology Agency
Nov 17, 2025 21:00 JST
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 14, 2025 00:41 JST
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 14, 2025 00:08 JST
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
NTT, NTT DOCOMO: Establishment of the AI Technology "Large Action Model (LAM)" to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:00 JST
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Announces TK-SR Rhodium Material for Use in Probe Pins
Nov 12, 2025 11:00 JST
Hitachi and Tobu Railway launched a co-creation initiative to deliver HMAX on Japanese railways
Nov 11, 2025 17:35 JST
World Premiere of the New Hilux in Asia
Nov 10, 2025 20:29 JST
More Latest Release >>